Trial reportCell reports. Medicine2026
Iparomlimab and tuvonralimab in previously treated patients with cervical cancer.
Trial report in Cell reports. Medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05557565 (A Single-arm, Open, Multicenter Phase II Trial to Evaluate the Efficacy and Safety of QL1706 in Patients With Recurrent or Metastatic Cervical Cancer), which is not on this map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Single-arm, Open, Multicenter Phase II Trial to Evaluate the Efficacy and Safety of QL1706 in Patients With Recurrent or Metastatic Cervical Cancer
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
20 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Iparomlimab and tuvonralimab (QL1706) is a bifunctional antibody containing anti-programmed death-1 IgG4 and anti-cytotoxic T-lymphocyte antigen 4 IgG1. This multi-center single-arm phase 2 trial recruits patients with recurrent or metastatic cervical cancer (r/m CC) who have failed at least first-line platinum-based chemotherapy with or without bevacizumab. QL1706 is administered at a dose of 5.0 mg/kg every 3 weeks via intravenous infusion. The primary endpoint is objective response rate (ORR) per independent review committee (IRC). In a total of 148 patients, the confirmed ORR and disease control rate are 33.3% (95% confidence interval [CI]: 25.8%-41.6%) and 65.3% (95% CI: 57.0%-73.0%) per IRC, respectively. The median progression-free survival is 5.4 months (95% CI: 3.9-6.9). The median overall survival is 17.1 months (95% CI: 14.8 to not evaluable). Treatment-related adverse events occur in 107 (72.3%) patients. No treatment-related death occurs. QL1706 shows promising efficacy and is well tolerated in previously treated patients with r/m CC. The trial is registered at clinicaltrials.gov (NCT05557565).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.